Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.

Changing the way antibiotics are developed and accessed.

A public-health driven model to tackle AMR.

Our latest news and resources.

Protecting people from the rise and spread of drug-resistant infections.

Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.

Multi-centric study to contain antimicrobial resistant neonatal sepsis begins in India

10 July 2026

Striking at the heart of antimicrobial resistance, the international NeoSep 1 trial to evaluate life-saving antibiotic combinations for newborns with sepsis has expanded to India, with the first baby being recruited at the Jawaharlal Postgraduate Education Institute of Medical and Research (JIPMER) in Puducherry.

This was followed by recruiting an infant for the study in Pt. B.D. Sharma PGIMS in Rohtak. The next on the list is Lokmanya Tilak Municipal College and General Hospital, Mumbai. Globally, the study, sponsored by the GARDP Foundation in collaboration with the UCL Innovative Clinical Trials Unit; City St George’s, University of London (SGUL), and Penta Foundation, is also underway in Vietnam and Pakistan, and will soon start in Malaysia, Bangladesh and Uganda.

READ FULL ARTICLE